GLUE vs KYMR
GLUE: Monte Rosa Therapeutics is a clinical-stage biotechnology company leveraging its proprietary protein degradation platform to develop targeted small molecule medicines for challenging diseases. KYMR: Kymera Therapeutics is pioneering oral, targeted protein degradation medicines designed to deliver biologic-like efficacy for underserved patients in immunology and beyond.
Side-by-side fundamentals
| Metric | GLUE | KYMR | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $10.32 | $109.30 | |
| Market cap as of 2026-07-31 (share count; price 2026-10-08) | $880M | $9.1B | |
| Net margin FY2025, SEC XBRL | n/a | -794.0% | |
| Operating margin FY2025, SEC XBRL | n/a | -891.1% | |
| ROE FY2025, SEC XBRL | -16.6% | -19.7% | GLUE higher |
| ROA FY2025, SEC XBRL | -8.6% | -17.9% | GLUE higher |
| Debt / equity as of 2026-09-03 | 0.00 | 0.00 | GLUE lower |
| Revenue growth (YoY) as of 2026-09-03 | -83.9% | n/a | |
| Revenue CAGR (3y) SEC XBRL | n/a | -5.7% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.05 | 1.44 | |
| 1-year return as of 2026-10-08 close | +33.9% | +94.2% | KYMR higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.